Diabetes News

Endocrinology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wimalawansa SJ et al. - BMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison to a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was -16 mg/day).

Exclusive Author Commentary
Sunil J. Wimalawansam, MD, PhD, MBA, 08/02/09

This single center, three-year double-blind, randomized, clinical study in 188 early postmenopausal subjects, half received 22.5 mg of transdermal nitroglycerin (average dose ~16 mg/day) plus calcium plus vitamin D, while the control group received a placebo ointment, calcium and vitamin D. The primary endpoint, the lumbar spine BMD did not differ significant; under dosing of subjects was the primary reason for this. Taken together with other studies, we believe that higher dosages would not only preserve BMD, but may also improve fracture rates. If this is proven the case, nitric oxide donors are likely to be the most cost-effective therapy for prevention and treatment of osteoporosis. Hence, new studies are warranted in this fires of research.

Today in Bone Metabolism...keeping you current

Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
International Journal of Women's Health, 12/18/09

Lateral back pain identifies prevalent vertebral fractures in post-menopausal women: Cross-sectional analysis of a primary care-based cohort
Rheumatology, 12/17/09

Fat Mass Exerts a Greater Effect on Cortical Bone Mass in Girls than Boys
Journal of Clinical Endocrinology and Metabolism, 12/17/09

Today in Pharmacology/kinetics...keeping you current

New therapies for the treatment of type 2 diabetes: an update
European Diabetes Nursing, 12/18/09

Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
International Journal of Women's Health, 12/18/09

Responses to Continuous Glucose Monitoring in Subjects with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion or Multiple Daily Injections
Diabetes Technology & Therapeutics, 12/17/09